Profile of salivary gland flow dysfunctions in patients with differentiated thyroid carcinoma submitted to radioiodine therapy

Abstract

AIM: To evaluate the effects of radioiodine therapy on salivary flow in patients with differentiated thyroid cancer. METHODS: A sample comprising 88 patients submitted to ablation with iodine 131 was included in the study. The patients were submitted to sialometry and evaluation of the presence of xerostomia before, 10 days and 3 months after radioiodine therapy. RESULTS: Xerostomia was observed in 36.4% of the patients before radioiodine therapy, 59.15% at 10 days after therapy, and 25% at 3 months after therapy. Significant differences were observed in non-stimulated salivary flow rates between the second and third evaluations (p<0.020) and in stimulated salivary flow between the first and second evaluations (p<0.010). CONCLUSIONS: The results suggest that changes in salivary flow resulting from radioiodine therapy are more pronounced during the first weeks after treatment and seem to regress after 3 months.

thyroid gland tumors; iodine radioisotopes; salivary glands; saliva; xerostomia; hyposalivation

• ¹
  Ward LS, Assumpção LV. Thyroid cancer: prognostic factors and treatment. Arq Bras Endocrinol Metabol. 2004; 48: 126-36.
• ²
  Van Nostrand D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis. 2011; 17: 154-61.
• ³
  Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O'Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001; 42: 738-43.
• ⁴
  Almeida JP, Sanabria AE, Lima EN, Kowalski LP. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck. 2011; 33: 686-90.
• ⁵
  Liu B, Kuang A, Huang R, Zhao Z, Zeng Y, Wang J, Tian R. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial. J Nucl Med. 2010; 51: 618-23.
• ⁶
  Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124)I PET(/CT) imaging. Eur J Nucl Med Mol Imaging. 2010; 37: 2298-306.
• ⁷
  Aframian DJ, Helcer M, Livni D, Markitziu A. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Dis. 2006; 12: 297-300.
• ⁸
  Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med. 2008; 49: 546-9.
• ⁹
  Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009; 50: 1605-10.
• ¹⁰
  Amenábar J M, Pawlowski J, Hilgert J B, Hugo FN, Bandeira D, Lhüller F, et al. Anxiety and salivary cortisol levels in patients with burning mouth syndrome: case-control study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105: 460-5.
• ¹¹
  Van den Berg I, Pijpe J, Vissink A. Salivary gland parameters and clinical data related to the underlying disorder in patients with persisting xerostomia. Eur J Oral Sci. 2007; 115: 97-102.
• ¹²
  Rosário PWS, Maia FFR, Barroso A, Padrão EL, Rezende L, Purish S. Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2004; 48: 310-4.
• ¹³
  Rosário PWS, Cardoso LD, Barroso AL, Padrão EL, Rezende LL, Purish S. Safety of radioiodine therapy in patients with thyroid carcinoma younger than 21 years. Arq Bras Endocrinol Metabol. 2005; 49: 241-5.
• ¹⁴
  Caglar M, Tungel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002; 27: 767-71.
• ¹⁵
  Van Nostrand D, Atkins F, Bandaru VV, Chennupati SP, Moreau S, Burman K, et al. Salivary gland protection with sialogogues: A case study. Thyroid. 2009; 19: 1005-8.
• ¹⁶
  Bomeli SR, Desai SC, Johnson JT, Walvekar RR. Management of salivary flow in head and neck cancer patients - a systematic review. Oral Oncol. 2008; 44: 1000-8.

Publication Dates

• Publication in this collection
  28 Oct 2013
• Date of issue
  Sept 2013

History

• Received
  30 Apr 2013
• Accepted
  31 July 2013